The Life Sciences team advised Bicycle Therapeutics plc (Bicycle) in its $60 million initial public offering of 4,333,333 American Depositary Shares, or ADSs, at a price to the public of $14.00 per ADS.
Bicycle’s shares began trading on The Nasdaq Global Select Market on May 23, 2019, under the ticker symbol “BCYC.” Goldman Sachs, Jefferies and Piper Jaffray served as joint book-running managers for the offering. Canaccord Genuity acted as a co-manager for the offering. The underwriters were granted a 30-day option to purchase up to an additional 650,000 ADSs.
Bicycle is a clinical-stage biopharmaceutical company developing a novel class of medicines, called Bicycles , which are fully synthetic short peptides constrained to form two loops that stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches.
The Goodwin team was led by partner Kris Brown and included partners James Xu, Graham Defries, Sarah Bock, Roger Cohen, Dan Karelitz and Ettore Santucci, associates Marishka DeToy, Kenny MacLeod, Michael Grainger, Karin Yoo, Monica Patel, Tim Holahan, Lee Douthitt, Bryna Shmerling, Andrew Wilson, Katie Leah, and trainee solicitor, with assistance from Mayan Katz and Pam Finan.For additional details on the offering, read the press release.